TR199701577T1 - Dopamin sistemindeki bozukluklara bagli hastaliklarin tedavisi. - Google Patents

Dopamin sistemindeki bozukluklara bagli hastaliklarin tedavisi.

Info

Publication number
TR199701577T1
TR199701577T1 TR97/01577T TR9701577T TR199701577T1 TR 199701577 T1 TR199701577 T1 TR 199701577T1 TR 97/01577 T TR97/01577 T TR 97/01577T TR 9701577 T TR9701577 T TR 9701577T TR 199701577 T1 TR199701577 T1 TR 199701577T1
Authority
TR
Turkey
Prior art keywords
alkyl
carbonyl
amino
hydrogen
treatment
Prior art date
Application number
TR97/01577T
Other languages
English (en)
Inventor
Godel Thierry
Hartman Deborah
Riemer Claus
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR199701577T1 publication Critical patent/TR199701577T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bulus, genel formül (I)'e sahip bilesiklerin kullanimi ile ilgilidir; burada R1= hidrojen, düsük alkil, halojen, düsük alkoksi veya nitro; R2= hidrojen, düsük alkil veya triflorometil; ve R3= hidrojen, düsük alkil, triflorometil, benzil, hidroksi-düsük-alkil, düsük alkoksi, düsük-alkil-karbonil-amino, karbonil-düsük-alkil, benzil, di-düsük-alkil-amino-karbonil, karbonil-amino veya amino-karbonil-amino; veya R2 ve R3 birlikte opsiyonel olarak birlesmis bir benzen halkasi ve R4= hidrojen veya halojen'i ifade etmektedir. Ayrica formül (I)'e sahip bilesiklerin farmasötik olarak kabul edilebilir tuzlarinin dopamin sistemindeki bozukluklara bagli hastaliklarin tedavisi veya önlenmesinde ve ilgili ilaçlarin üretimlerinde kullanilmasi ile ilgilidir.
TR97/01577T 1995-06-09 1996-06-04 Dopamin sistemindeki bozukluklara bagli hastaliklarin tedavisi. TR199701577T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH170495 1995-06-09

Publications (1)

Publication Number Publication Date
TR199701577T1 true TR199701577T1 (tr) 1998-06-22

Family

ID=4216657

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/01577T TR199701577T1 (tr) 1995-06-09 1996-06-04 Dopamin sistemindeki bozukluklara bagli hastaliklarin tedavisi.

Country Status (14)

Country Link
US (1) US5698565A (tr)
EP (1) EP0837680B1 (tr)
JP (1) JP3004732B2 (tr)
AT (1) ATE198984T1 (tr)
AU (1) AU6300396A (tr)
BR (1) BR9609196A (tr)
CA (1) CA2222226A1 (tr)
DE (1) DE69611727T2 (tr)
DK (1) DK0837680T3 (tr)
ES (1) ES2154828T3 (tr)
GR (1) GR3035703T3 (tr)
PT (1) PT837680E (tr)
TR (1) TR199701577T1 (tr)
WO (1) WO1996041629A1 (tr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032581A1 (en) * 1996-03-08 1997-09-12 F. Hoffmann-La Roche Ag Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816434A (en) * 1966-06-24 1974-06-11 Hoffmann La Roche 4-(3-(4-phenyl-piperidino)-2-hydroxy-propoxy)-benzophenones
CH474511A (tr) * 1966-06-24 1969-06-30 F. Hoffmann-La Roche & Co. Aktiengesellschaft
NL133317C (tr) * 1966-06-24 1900-01-01
CH507240A (de) * 1968-12-24 1971-05-15 Hoffmann La Roche Verfahren zur Herstellung von aromatischen Äthern
CH558354A (de) * 1970-06-17 1975-01-31 Hoffmann La Roche Verfahren zur herstellung von aromatischen aethern.
JPS57145872A (en) * 1981-03-05 1982-09-09 Otsuka Pharmaceut Co Ltd Carbostyrile derivative
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
HU211019B (en) * 1991-12-02 1995-09-28 Richter Gedeon Vegyeszet Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds

Also Published As

Publication number Publication date
JP3004732B2 (ja) 2000-01-31
PT837680E (pt) 2001-07-31
CA2222226A1 (en) 1996-12-27
GR3035703T3 (en) 2001-07-31
AU6300396A (en) 1997-01-09
DE69611727D1 (de) 2001-03-08
EP0837680A1 (en) 1998-04-29
MX9709393A (es) 1998-07-31
ES2154828T3 (es) 2001-04-16
DE69611727T2 (de) 2001-08-23
EP0837680B1 (en) 2001-01-31
JPH10506651A (ja) 1998-06-30
US5698565A (en) 1997-12-16
ATE198984T1 (de) 2001-02-15
WO1996041629A1 (en) 1996-12-27
BR9609196A (pt) 1999-05-11
DK0837680T3 (da) 2001-05-07

Similar Documents

Publication Publication Date Title
KR960700707A (ko) 맥관형성 억제제로서 유용한, 생물학적 활성의 3-치환된 옥신돌 유도체(Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents)
NO305656B1 (no) Nye dihydropyridinforbindelser, farmas°ytiske preparater inneholdende slike forbindelser samt anvendelse av forbindelsene
DE69412016T2 (de) Substituierte arylalkoxybenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
ES8401460A1 (es) Un procedimiento para preparar derivados de benzamida.
DE69402935D1 (de) Substituierte arylalkylaminobenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
ATE218535T1 (de) Aminotetralinderivate, deren zusammensetzungen sowie deren verwendung
NO308658B1 (no) Sammenføyde isoquinoliner som dopamin-reseptor-ligander
TR199701577T1 (tr) Dopamin sistemindeki bozukluklara bagli hastaliklarin tedavisi.
DE69526584T2 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
CA2050875A1 (en) 3-(1h-indazol-3-yl)-4-pyridinamines, a process and intermediates for their preparation and their use as medicaments
PT1082116E (pt) Utilizacao de derivados de 4-piperidinometanol no tratamento de desordens do neurodesenvolvimento
WO1994016705A3 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders